Core Viewpoint - Weigao Blood Products (603014) experienced a 2.73% increase in stock price with a trading volume of 5.34 billion yuan and a turnover rate of 30.19% on the day of reporting [1] Trading Activity - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its turnover rate reaching 30.19%, with a net selling amount of 30,250 yuan from brokerage seats [1] - The top five brokerage seats accounted for a total transaction volume of 1.01 billion yuan, with buying transactions amounting to 50.35 million yuan and selling transactions totaling 50.65 million yuan, resulting in a net sell of 30,250 yuan [1] - The largest buying brokerage was Southwest Securities, with a purchase amount of 19.10 million yuan, while the largest selling brokerage was East Asia Qianhai Securities, with a selling amount of 17.21 million yuan [1] Financial Performance - For the first three quarters, the company reported a total revenue of 2.736 billion yuan, reflecting a year-on-year growth of 3.45%, and a net profit of 341 million yuan, which is a year-on-year increase of 7.92% [2] - Over the past six months, the stock has appeared on the "Dragon and Tiger List" six times, with an average price drop of 2.84% the day after being listed and an average decline of 3.97% over the following five days [1] - The stock saw a net inflow of 15.59 million yuan from major funds today, with a significant single order net inflow of 18.45 million yuan, while large orders experienced a net outflow of 2.86 million yuan [1] - In the last five days, the net inflow of major funds amounted to 134 million yuan [1]
威高血净11月6日龙虎榜数据